Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MASTERPLAN: A Randomised Phase II Study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease

NCT04089150 is registered in ClinicalTrials.gov with Australasian Gastro-Intestinal Trials Group as lead sponsor.

NCT NCT04089150
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04089150 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MASTERPLAN: A Randomised Phase II Study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease
Lead sponsor
Australasian Gastro-Intestinal Trials Group
Phase
Phase 2
Overall status
Unknown status
Start date
October 1, 2019
Completion date
August 30, 2023
Enrollment
120 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer